Healthcare is rarely out of the headlines. One day, the conversation centers on rising costs. The next, it’s physician shortages, access to care, insurance reform, or the latest medical breakthrough. Each issue deserves attention because every one affects patients in meaningful ways. But amid all of these discussions, I think we sometimes lose sight of a more fundamental question.

Most people think progress in cancer research happens in big moments. A breakthrough. A headline. A new treatment. What they don’t see is everything that happens before that. The years of work. The failed experiments. The collaboration across institutions. The early ideas that don’t yet have enough data to qualify for traditional funding. That’s where a lot of the real progress starts. And it’s where cancer research philanthropy can make a meaningful difference.

But what they don’t see is the grind behind the scenes. The years of effort, the research that doesn’t get funded, and the scientists struggling to keep momentum without institutional support.

Every field has its trends, and science is no exception. One year, it’s immunotherapy. Next, it’s AI in diagnostics. Big breakthroughs and high-impact journals are great. But when funding begins to chase popularity instead of substance, something gets lost. The cost of chasing what’s popular in science is high. It’s paid by researchers working on foundational problems who can’t get funded. It’s paid by patients waiting for treatments that don’t check the right boxes. And it’s